Business Context and Reporting Period
Company: Accuray Incorporated (ARAY)
Filing Type: Form 8-K (Current Report)
Date of Report: July 3, 2020
Event: Entry into a Material Definitive Agreement involving amendments to existing credit facilities.
Key Financial Metrics
This filing does not report specific financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The document focuses exclusively on the modification of debt covenants.
Material Changes
On July 3, 2020, Accuray Incorporated entered into two amendments to its existing credit agreements:
- Revolving Loan Amendment: Amended the Revolving Credit Agreement dated June 14, 2017.
- Term Loan Amendment: Amended the Term Loan Agreement dated December 15, 2017.
- Primary Change: Both amendments were executed to modify certain financial covenant requirements.
- Parties Involved: The Borrowers (Accuray and its subsidiary TomoTherapy Incorporated) and lenders including Midcap Funding IV Trust and MidCap Financial Trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk disclosures beyond the standard legal qualification that the summary is subject to the full text of the Amendments. The full text of the Amendments is noted to be filed as exhibits to the Company's Annual Report on Form 10-K for the year ended June 30, 2020.
Investor Verification Checklist
- Review the full text of the Revolving Loan Amendment and Term Loan Amendment (to be filed as exhibits to the 2020 Form 10-K) to understand the specific changes to financial covenants.
- Verify the current status of the Company's compliance with the newly modified covenants.
- Confirm the identity and terms of the lenders (Midcap Funding IV Trust and MidCap Financial Trust) under the amended agreements.